Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma

Authors:

Abstract
No abstract available
Funding Information
  • National Natural Science Foundation of China (81330076, 81773762)
  • Personalized Medicines—Molecular Signature-based Drug Discovery and Development
  • Chinese Academy of Sciences (XDA12020323)
  • National Science & Technology
  • “Key New Drug Creation and Manufacturing Program” of China (2018ZX09711002-004)

This publication has 17 references indexed in Scilit: